SAN FRANCISCO, June 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has begun offering early access to its new Personalized Cancer Monitoring (PCM™) platform as a laboratory-developed test performed at an Invitae central laboratory.
Read MoreDMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. Processing was done at EW Biotech in Leuna, Germany, following the successful demonstration of commercial scale fermentation at the same site in March.
Read MoreBoulder County, CO -More than 191,000 residents or 70% of the eligible population (16 years and older in the state’s prioritization Phases 1 and 2) in Boulder County has received at least one course of the COVID-19 vaccine in one of the biggest mass vaccination efforts since the polio vaccine in the 1950s.
Read MoreSAN FRANCISCO, May 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021.
Read MoreBill Whitaker reports on some of the innovations being developed to try to prevent the next pandemic. See the story Sunday on 60 Minutes.
BROOMFIELD, Colo., March 31, 2021 /PRNewswire/ -- Redeam, the leading and only independent global connectivity stack with digitized channel management and touchless voucher redemption/reconciliation solutions for the Things To Do sector of travel, today announced it had completed a $12M Series B funding raise.
Read MoreLong stigmatized in the United States, wider adoption of guided backcountry skiing will boost knowledge, reduce gatekeeping, and promote human-powered skiing on public lands.
Read MoreRESTON, VA—(BUSINESS WIRE, February 18, 2021)—Clarabridge, Inc., the leading provider of Customer Experience Management (CEM) solutions for the world’s top brands, experienced a record-breaking year in 2020, with 300% increase in new customers sales YoY in Q4 and growth in overall deal size driven by speech analytics.
Read MoreOver the past 40 years, the vast majority of therapeutics that entered human testing failed to make it to market. Over the past 20 years – and really accelerating over the past 5 years – new technologies and clinical development strategies emerged that made it possible to dramatically improve on those historically dismal rates. “Precision medicine” holds the promise of the right medicine for the right patient at the right time, and represents a paradigm change from the empirical medicine practiced in the past.
Read More